Govt. to augment Covaxin production by 10 crore doses
Financial support is being provided as a grant from the Government of India
Financial support is being provided as a grant from the Government of India
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Acquisition of A&C expands Aceto’s Western manufacturing footprint
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
PEL will explore the PLI scheme and apply if its beneficial.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Subscribe To Our Newsletter & Stay Updated